» Articles » PMID: 11316142

Intragastric Acidification Reduces the Occurrence of False-negative Urea Breath Test Results in Patients Taking a Proton Pump Inhibitor

Overview
Specialty Gastroenterology
Date 2001 Apr 24
PMID 11316142
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to investigate whether reducing intragastric pH, at the time of urea ingestion, decreases the likelihood of false-negative (FN) urea breath test (UBT) results in patients taking a proton pump inhibitor (PPI).

Methods: Patients with active Helicobacter pylori infection underwent a baseline 14C-UBT (UBT-1) followed by treatment with lansoprazole 30 mg/day for 14 to 16 days. On day 13, patients returned for a repeat standard UBT (UBT-2). Between days 14 to 16, patients underwent a modified UBT (UBT-3), which included consuming 200 ml of 0.1 N citrate solution 30 min before and at the time of 14C-urea administration. Breath samples were collected 10 and 15 min after 14C-urea ingestion. Mean 14CO2 excretion and the number of FN and equivocal UBT results were compared for the three UBTs.

Results: A total of 20 patients completed the study. Lansoprazole caused a significant decrease in mean breath 14CO2 excretion (disintegrations per minute) between UBT-1 (2.96 +/- 0.23) and UBT-2 (2.08 +/- 0.52, p < 0.05). Lansoprazole caused six (30%) FN and eight (40%) equivocal UBT-2 results. Mean breath 14CO2 excretion for UBT-3 (677 +/- 514) was greater than for UBT-2 (234 +/- 327, p = 0.001). UBT-3 caused only two (10%) FN and three (15%) equivocal results. The 15-min breath sample caused fewer FN and equivocal results than the 10-min sample for both UBT-2 and UBT-3.

Conclusions: Giving citrate before and at the time of 14C-urea administration increases mean breath 14CO2 excretion and decreases FN and equivocal UBT results in patients taking a PPI. These observations suggest that it may be possible to design a UBT protocol that will remain accurate in the face of PPI therapy.

Citing Articles

Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Ansari S, Yamaoka Y Clin Microbiol Rev. 2022; 35(3):e0025821.

PMID: 35404105 PMC: 9491184. DOI: 10.1128/cmr.00258-21.


Modified test using a new test meal and a C-urea breath test in positive and negative dyspepsia patients on proton pump inhibitors.

Tepes B, Malfertheiner P, Labenz J, Aygen S World J Gastroenterol. 2017; 23(32):5954-5961.

PMID: 28932087 PMC: 5583580. DOI: 10.3748/wjg.v23.i32.5954.


Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the C-Urea Breath Test in Helicobacter pylori-Positive Patients.

Takimoto M, Tomita T, Yamasaki T, Fukui S, Taki M, Okugawa T Dig Dis Sci. 2017; 62(3):739-745.

PMID: 28083842 DOI: 10.1007/s10620-016-4439-0.


Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.

Nasser S, Slim M, Nassif J, Nasser S World J Gastroenterol. 2015; 21(15):4599-606.

PMID: 25914469 PMC: 4402307. DOI: 10.3748/wjg.v21.i15.4599.


Effect of gastric acidification on the (14)C-UBT HELIPROBE(®) accuracy during Pantoprazole treatment in Helicobacter pylori positive patients.

Mansour-Ghanaei F, Joukar F, Sheykhian M, Soati F, Rafatzand A Int J Clin Exp Med. 2013; 6(3):185-91.

PMID: 23573349 PMC: 3609694.